Here are the DEF 14A proxy statements from MapLight Therapeutics, Inc. (MPLT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.
MapLight Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 23, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of April 27, 2026, when 42,610,079 shares of voting common stock were outstanding, may vote online, by telephone or by mail.
Stockholders will vote on two proposals: the election of three Class I directors (Martin Babler, Troy Cox and incumbent George Pavlov) to terms expiring at the 2029 annual meeting, and the ratification of RSM US LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends a vote “FOR” all director nominees and “FOR” auditor ratification.
The proxy describes MapLight’s classified board structure, committee composition, independence determinations and governance policies, including an insider trading policy, anti-hedging and anti-pledging rules, and a clawback policy. It also details executive and director compensation, including 2025 salaries, cash bonuses and equity awards, along with a severance and change-in-control plan covering senior executives.